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Abstract
Amyotrophic Lateral Sclerosis (ALS) is a late-onset, progressive neurodegenerative disease affecting motor neurons in the
brain stem and spinal cord leading to loss of voluntary muscular function and ultimately, death due to respiratory failure. A
subset of ALS cases are familial and associated with mutations in superoxide dismutase 1 (SOD1) that destabilize the protein
and predispose it to aggregation. In spite of the fact that sporadic and familial forms of ALS share many common patho-
physiological features, the mechanistic relationship between SOD1-associated and sporadic forms of the disease if any, is
not well understood. To better understand any molecular connections, a cell-based protein folding assay was employed to
screen a whole genome RNAi library for genes that regulate levels of soluble SOD1. Statistically significant hits that
modulate SOD1 levels, when analyzed by pathway analysis revealed a highly ranked network containing TAR DNA binging
protein (TDP-43), a major component of aggregates characteristic of sporadic ALS. Biochemical experiments confirmed the
action of TDP-43 on SOD1. These results highlight an unexpected relationship between TDP-43 and SOD1 which may have
implications in disease pathogenesis.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a progressive neurode-
generative disease that affects motor neurons in the brain stem and
spinal cord. Patients afflicted with severe forms of the disease have
a median survival time of less than 2 years after the appearance of
the symptoms [1,2]. The loss of motor neurons leads to defects in
voluntary muscular activities such as breathing, walking, swallow-
ing etc. and fatality occurs usually due to respiratory failure.
Aggregated proteinaceous inclusions have been found in the cell
bodies of motor neurons derived from patients and mouse models
[2,3]. The aggregates can contain a variety of ubiquitinated
proteins including TAR DNA binding protein (TDP-43) or
superoxide dismutase 1 (SOD1) [2,4,5].
SOD1 is a detoxification enzyme, that catalyzes the conversion
of superoxide to hydrogen peroxide [6]. Mutations in SOD1
constitute a significant share (,20%) of all familial ALS cases [2].
These mutations destabilize SOD1 and promote aggregate
formation [7]. TDP-43 is a RNA-DNA binding protein reported
to be involved in transcription, splicing and RNA stability [8].
Recent studies suggest that TDP-43 self-regulates its own levels by
altering the splicing of its transcripts [9]. TDP-43 aggregates are
found in patients with sporadic disease and in most familial
versions, excepting SOD1-linked ALS [4]. A subset of familial
ALS is associated with mutations in TDP-43 that promote its
aggregation [10]. In addition to SOD1 and TDP-43, mutations in
several other proteins including progranulin, alsin, senataxin have
been associated with fALS. None of these proteins have
demonstrated molecular connections.
Regardless of the proteins present in the aggregates, sporadic
and familial ALS cases share many patho-physiological charac-
teristics, including inclusion formation, vacuolization of the cell
bodies, oxidative damage, motor neuron loss and attendant
physiological symptoms [11], suggesting that common molecular
processes may lead to the disease phenotype. Unfortunately there
is currently a dearth of knowledge about molecular mechanisms
that link the patho-physiology of the various sporadic and familial
forms of the disease. Some reports suggest that sporadic ALS and
SOD1 linked ALS occur due to completely independent
mechanisms [12]. To test this hypothesis and to potentially reveal
putative underlying molecular connections between the SOD1-
linked familial ALS and the other proteins implicated in the
disease, an RNAi screen for proteins that regulate soluble levels of
SOD1 was performed.
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35818An extant reporter assay [13,14] that monitors the solubility of
proteins in cells was utilized to screen a genome-wide RNAi
library for cellular modulators that affect mutant SOD1 solubility
and folding. The assay is based on the structural complementation
of the two b-galactosidase fragments to form an active enzyme in
cells, which can be monitored. The reporter assay consists of
SOD1 protein fused to a small fragment (a) of the b-galactosidase
enzyme, which is co-expressed with the larger v fragment.
Changes in the soluble levels of mutant SOD1 are linked to
availability of the a fragment and are reflected by a change in the
assay signal. Thus, knocking down genes from the whole genome
may alter the signal, up or down, depending upon their effect on
SOD1 solubility, transcription, translation, protein stability or
degradation. The hits from the screen were analyzed using
pathway analysis software, which identified a network involved in
Skeletal and Muscular System Development and Function, Tissue
Morphology and Inflammatory Response. Among the hits
represented in the network was TDP-43, which dramatically
increased the SOD1 assay signal upon knockdown. Validation
experiments with TDP-43 knockdown and overexpression con-
firmed the regulatory role of TDP-43 on SOD1. These findings
suggest that this TDP-43 and SOD1 connection provides a link
between familial and TDP-43 linked sporadic ALS.
Results
Assay development
An assay that monitors the levels of soluble protein inside cells
was used in this study [13,14]. The assay relies upon structural
complementation between mutant SOD1 fused with the a
fragment of b-galactosidase and the v fragment of b-galactosidase
to regenerate enzymatic activity [15], which can then be measured
using a fluorogenic or luminogenic substrate (Figure S1).
A4VSOD1-HA-a fusion expression was driven by a minimal
human SOD1 promoter [16,17] and v fragment expression driven
by a CMV promoter. When these reporter plasmids were co-
expressed in mammalian cells, the amount of b-gal activity
observed was directly correlated to the amount of soluble SOD1
present in cells [14]. Any cellular process that affects the levels of
SOD1 will be reflected in the assay signal. For instance, when
proteasome activity was inhibited with MG 132, the levels of the
SOD1 fusion increased as observed by western blot, resulting in
increased assay signal [14].
A similar effect would be expected upon knockdown of the
components of proteasome. siRNA targeted against the S4
(PSMC1) subunit of 26 S proteasome was transfected into HeLa
TetOn cells expressing the components of the reporter assay.
Assessment of the b-gal activity (soluble SOD1 levels) revealed an
increase in fluorescence signal in the samples treated with S4
siRNA (Figure 1A). SOD1 protein levels were found to be elevated
when tested in a western blot analysis with probes detecting SOD1
(data not shown). To establish that the observed effect on SOD1
levels was due to the depletion of the S4 subunit of proteasome,
samples were analyzed by immunoblot with anti S4 antibody. The
results showed .90% knockdown of the S4 protein (data not
shown). These results confirmed that proteasomal inhibition
through siRNA can be used to optimize the assay for high-
throughput screening.
Since the whole genome RNAi library was distributed in 96 well
plates, the assay was optimized in this format by systematically
varying the reporter plasmid ratios, DNA concentration, trans-
fection reagent volume, cell numbers, incubation time, and plate
reading conditions [18]. The influence of one such change
involving DNA ratios and amounts significantly improved assay
quality (Figure 1B). HeLa-TetOn cells pretreated with S4 siRNA
or with no siRNA were transfected with reporter plasmids (SOD1
promoter driven A4VSOD1-HA-a and CMV promoter driven v)
in 1:1, 2:1, 3:1 and 4:1 ratios (a:v) and were incubated for 96 hrs
prior to analysis of b-gal activity by the addition of a luminogenic
substrate. Cells transfected with plasmids in the ratio 4:1 had b-gal
activity in the response range. The Z9 factor of this condition was
greater than 0.5, a minimum threshold, thus, indicating the assay
is suitable for high throughput screening [19].
Screening of the whole genome RNAi library
siRNA pools of four oligonucleotides targeting each of 21,125
human proteins were screened under these optimized assay
conditions (Figure S2). The results from the screen were analyzed
by two different methods; MAD score, a median based method
[20] and Z-score, a mean based method. Plots of the screening
data processed by the MAD and Z score based methods are shown
in Figure 2A and 2B respectively. There is a high degree of
correlation between the hits processed by both methods, viz., close
to 90% of the hits from the Z-score method were present in the
MAD score based hits. The MAD based method is less prone to
plate artifacts and outliers and was chosen for further analyses.
The normalized raw data was also used to calculate the q*-value
[21] for the assessment of false discovery rate (FDR). There were
291 hits selected above 3 MAD and 150 hits below 22 MAD. A
relaxed cut-off value of 22 MAD was selected due to a shallow
assay floor as the signal reached closer to the background signal.
The hits with MAD scores .3MAD and ,22MAD were used for
pathway analysis.
Functional classes of proteins that modulate SOD1 levels
The hits from the siRNA screen that met the selection criteria
were classified broadly in to functional categories and a pie chart
summarizing the prominent functional processes of the proteins
that affected SOD1 levels are shown in Figure 3A&B. Among the
targets whose knockdown increased SOD1 levels were proteins
involved in regulation of transcription and G-protein coupled
receptor signaling. Those whose knockdown decreased SOD1
levels were proteins essential for protein biosynthesis, G-protein
coupled receptor signaling and regulation of transcription. The
MAD scores calculated for selected targets, such as, SOD isoforms
and ribosomal proteins were consistent with expectations. For
example, siRNA targeting SOD1 lowered the levels of the reporter
levels significantly (22.4 MAD score) and had a very low q* value
(FDR), whereas ones that target SOD2 (0.25 MAD score) or
SOD3 protein (0.8 MAD score), had no significant effect
(Figure 3C). Knockdown of many proteins that are part of the
ribosomal protein machinery, as expected, lowered the levels of
reporter signal (data not shown).
Pathways analysis
The hits were analyzed for potential relationship with
established networks, by Ingenuity pathway analysis (IPA)
software. The leading interaction network generated by the IPA
program based upon the highest score is shown in Figure 4. The
network represents proteins annotated under ‘‘Skeletal and
Muscular System Development and Function, Tissue Morpholo-
gy, Inflammatory Response’’ and contains over 40 proteins that
either increased the SOD1 levels .3MAD, represented in red, or
that decreased SOD1 levels ,22MAD, represented in green. It is
interesting to note that one of the nodes in the interaction network
is the TARDBP, Tar DNA binding protein (TDP-43) (Inset in
Figure 4). This is a multi-domain RNA, DNA binding protein,
reportedly involved in transcriptional regulation, RNA splicing,
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in ALS disease pathogenesis due to its presence in proteinaceous
aggregates isolated from sporadic ALS patients and most forms of
familial ALS patients, except SOD1-linked forms [4,5]. The
identification of TDP-43 as one of the regulators of SOD1 in an
RNAi screen suggested an unexpected link between these proteins.
Validation of the TDP-43 effect on SOD1
In order to confirm the effect of TDP-43 knockdown on SOD1
in the RNAi screen we carried out independent experiments by
transfecting HeLa TetOn cells with the TDP siRNA pool followed
by monitoring soluble SOD1 levels utilizing the reporter system.
Again, upon TDP knockdown, SOD1 levels increased several fold
above the control siRNA transfected cells (Figure 5A), confirming
Figure 1. Optimization of the reporter assay for high throughput format. A) Effect of knock down of a proteasomal subunit on SOD1 levels.
HeLa cells were transfected with siRNA targeting the S4 subunit (PSMC1) of the 26 S proteasome, followed by expression of the mutant SOD1
reporter plasmids. Supernatant fractions were tested for b-gal activity by measuring the fluorescence signal. The plot shows SOD1 levels as a measure
of b-gal activity. B) HeLa cells were co-transfected with S4 siRNA or carrier and varying amounts of plasmids coding for A4VSOD1-HA-a fusion with a
fixed amount of v fragment. Cells were analyzed for fluorescence 96 hrs post transfection. The SOD1 levels measured as a function of b-gal activity
are plotted against each transfection condition. Z9 factor was used to assess the assays suitability for HTS.
doi:10.1371/journal.pone.0035818.g001
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43 and not because of off-target effects of the siRNA, human
TDP-43 was over-expressed and SOD1 levels were monitored
with the reporter system. In contrast to the increase in SOD1
caused by knockdown, increased TDP-43 expression led to a
reduction in SOD1 levels (Figure 5A). The knockdown of TDP-43
and its over expression were confirmed by the anti TDP western
blot (Figure S3). These results confirm that TDP-43 can negatively
regulate soluble SOD1 levels.
To further validate the screen and the relevance of the TDP-43
linked protein interaction network (Figure 4), ten additional targets
identified in the screen (6 targets that increased and 4 targets that
decreased SOD1 levels upon knockdown in the screen) were
selected. The siGenome siRNA pools targeting the 10 target genes
in addition to TDP-43 were independently transfected in to HeLa
TetOn cells followed by transfection of the reporter plasmids. The
change in SOD1 levels monitored by b-gal assay (Figure S4 A
(upper left and right panels) reaffirmed that knockdown of 9 of the
11 targets resulted in statistically significant changes in SOD1
expression. A decrease in the corresponding target message levels
upon knockdown with each siRNA pool was confirmed by
quantitative PCR (qPCR) analysis (Figure S4 A, lower panel). To
evaluate off-target effects of the siRNA pools, experiments were
carried out with independent siRNA (On Target Plus) designed
against regions of the target proteins distinct from those utilized by
the pooled siGenome siRNAs. Five of the nine targets, including
TDP43, (Figure S4 B, left panel) exhibited statistically significant
changes in the SOD1 levels (measured by b-gal assay), in a
direction consistent with that observed in the screen. To verify that
the On Target plus siRNAs reduced the target message levels,
qPCR was carried on these 5 samples. Significant decrease in the
messenger RNA levels was observed (Figure S4 B, right panel) for
all. In addition, western blot analysis of samples from cells treated
with siGenome siRNA pools or On Target plus siRNA showed
clear decreases in the protein levels of all 4 targets assessed (Figure
S4 C) further supporting the influence of these 5 targets on SOD1
expression.
TDP-43 regulates SOD1 mRNA level
TDP-43 has been reported to be involved in many cellular
functions including DNA/RNA binding, transcriptional repres-
sion, and splicing [8,22–26]. Thus, the SOD1 modulating function
of TDP-43 observed here could reasonably result in altered
mRNA levels. To determine whether the TDP-43 effect altered
SOD1 mRNA levels, total RNA isolated from cells treated with
TDP-43 siRNA or control siRNA was analyzed by qPCR. SOD1
mRNA levels increased three fold upon TDP-43 knockdown
(Figure 5B), which could indicate increased transcription and/or
mRNA stability. The results, however, can not be explained by a
splicing effect on SOD1 as cDNA used in SOD1 fusion expression
construct lacked intronic regions. These results do not preclude a
contribution of other mechanisms, such as effects on the protein
turnover rates, contributing to the increase in soluble SOD1
observed after TDP-43 knockdown.
Taken together, these results demonstrate an unexpected
function for TDP-43 as a regulator of SOD1. In view of these
findings, the mislocalization and aggregation of TDP-43 observed
in both sporadic and some familial versions of ALS [12] may have
functional consequences for SOD1 and predisposition to degen-
eration.
Discussion
Most neurodegenerative diseases, including Alzheimers, Par-
kinson and Amyotrophic lateral sclerosis, have a common
underlying etiology in their pathogenesis; a protein(s) misfolds
and accumulates in an intracellular or extra cellular environment
[27,28]. Concomitantly there is a series of poorly understood
events that lead to degeneration of a selective subset of cells
resulting in the loss of function. In ALS, several aberrant
regulatory processes have been reported, such as, mitochondrial
dysfunction [29], vacuolization [30], glutamate cytotoxicity
[31,32], axonal retrograde transport [33] and oxidative stress
[34,35]. Some of these regulatory pathways have been linked to
one another in a sequential manner [35], while there are many
that are obviously not connected. In spite of these complexities,
there are many common features of disease pathogenesis between
sporadic and familial, SOD1-dependent, ALS [11,36–38] suggest-
ing that common, but unknown, molecular mechanisms are at
work. Identifying and deciphering these connections is thus vital to
understanding the disease and for effectively developing therapies.
In the present work, this issue has been approached by starting
from a known attribute; that misfolded mutant SOD1 is linked to
familial amyotrophic lateral sclerosis and utilizing a functional
genomic approach to identify cellular proteins involved in
regulation of this attribute. A cell-based, b-galactosidase assay
that monitors SOD1 solubility/folding in cells, [13,14] was
adapted for the whole genome RNAi screening. Earlier studies
[14] had demonstrated that blockage of the proteasome by
MG132, leads to the elevation of the assay signal due to
accumulation of SOD1. However, inhibitors were not suitable
for optimizing the assay for an RNAi screen, because of the
differences in the treatment procedures. Thus, siRNA targeting S4
(PSMC1), a component of 26 S proteasome was selected and used
for assay optimizations (Figure 1A). Screening for modulators of
SOD1 solubility/folding was carried out utilizing a whole genome
RNAi library containing siRNA pools targeting 21,125 targets,
thus providing a near comprehensive scan of genomic proteins.
The screen results were processed using two independent statistical
methods (MAD score and Z score) minimizing the influence of any
anomalies introduced by a particular approach (Figure 2A and
2B). The screen results underrepresented the hits that lowered the
level of SOD1 below the typical hit selection threshold of 23SD
due to a threshold effect. The range of MAD score values reflects
this phenomenon (13 MAD to ,26 MAD). Thus, a relaxed hit
selection criterion of 22SD was selected to compensate. When the
hits that belonged to the selection criteria were classified in to
functional categories, it revealed that proteins from the G-protein
coupled receptor super family were involved in both up and down-
regulation of soluble SOD1 levels (Figure 3A & 3B), demonstrating
the complexity of the GPCR signaling network. Further, the
occurrence of transcriptional and translational regulatory proteins
among the top classes of protein targets involved in up or down
Figure 2. Distribution of b-gal assay signal in the genome wide RNAi screen. A) Luminescence intensity measurements of the genome wide
RNA screen of 21125 wells in triplicates were processed by MAD score analysis method and the results are plotted against well numbers. Horizontal
dotted lines indicate the hit selection criteria of +3 MAD or 22MAD. The two numbers listed in the plot represent the total number of hits that meet
the two selection criteria. B) Luminescence intensity measurements in triplicates were processed by Z score analysis method and the results are
plotted against well numbers. Horizontal dotted lines indicate the hit selection criteria of +3S Do r22SD. The numbers listed in the plot represent the
total number of hits that meet the hit selection criteria.
doi:10.1371/journal.pone.0035818.g002
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proteins identified as regulators of SOD1. Contribution of each biological process as a percentage of total are shown. Contributions of processes that
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protein expression levels. In addition, the leading biological
processes including GPCR signaling and transcriptional regulation
from the RNAi screen, represented many of the cellular
modulators of superoxide dismutase 1 identified from an earlier
expression cloning screen [14]. Human counterparts of 6 of the 10
murine proteins [14] that were identified in the earlier screen
(Table S2) had MAD scores indicating decreased SOD1
expression upon knockdown. Thus, levels of these targets correlate
with levels of SOD1; increased expression leads to increased
SOD1 and decreased expression, reduces SOD1.
Pathway analyses of the hits from the RNAi screen revealed
many protein interaction networks. The network named ‘‘Skeletal
and Muscular System Development and Function, Tissue
Morphology, Inflammatory Response’’ with the highest score
contained over 40 proteins that met the hit criteria (Figure 4). A
protein of particular interest in the network because of its
relationship to the ALS was the TAR DNA binding protein or
TDP-43. TDP-43 is a 414 amino acid, 43 kDa protein that
regulates gene expression at the level of transcription, splicing and
mRNA stability [39]. Aggregates of TDP-43, including phosphor-
ylated and truncated forms are found in sporadic and many
familial forms of ALS [40]. The molecular mechanism(s) by which
misfolding of TDP-43 or formation of its aggregates lead to
neurodegeneration is poorly understood. A linkage between TDP-
43 and SOD1 is suggested not only by the related pathology, but
also because of apparent reciprocal relationship of the two proteins
in inclusions [26]. TDP-43 aggregates are not observed in familial
SOD1-associated ALS patients that harbor SOD1 inclusions.
However, it should be noted that TDP-43 has been found to be
mis-located to the cytosol [41,42] in some of these patients. It has
also been hypothesized that SOD1 dependent and independent
ALS (sporadic and other forms of familial ALS) arise from
independent mechanisms [12].
In addition to TDP-43 protein, other TDP-43 associated gene
products in the top network also significantly affected SOD1 levels
upon knockdown, highlighting the relevance of the network in
SOD1 regulation (Figure 4, Table S1). In addition SETDB1, a
histone methyl transferase linked to TDP-43 in the network based
on its interaction identified in a mass-spectrometry based
proteomics study [43] significantly affected SOD1 levels (MAD
score 5.3) upon its knockdown. SETDB1 knockdown increased the
soluble SOD1 levels both in the screen (Figure 4 and Table S1)
and in independent experiments (data not shown). Further,
RBMX, a hetero-nuclear Ribonucleo protein (hnRNP) identified
among the hits in the top network with a MAD score of 9.9,
belongs to the same family of RNP’s that has been reported to
interact with TDP-43 [44–46]. These observations further support
the involvement of TDP-43 in the regulation of SOD1.
Validation experiments confirm that the action of TDP-43 on
SOD1 observed in the RNAi screen. The lowering of the TDP-43
levels with siRNA treatment resulted in the concomitant increase
in SOD1 levels (Figure 5A). A converse experiment showing
increased TDP-43 expression resulted in a suppression of SOD1
expression as measured by b-gal activity (Figure 5A). The inverse
correlation between increased TDP-43 and decreased SOD1
expression suggests a repressor role for TDP-43. Such a repressor
function of TDP-43 on select gene targets has been observed by
others [23,26,47]. The validation of 5 out of 11 target genes from
the TDP-43 linked protein interaction network as regulators of
SOD1 expression (Figure S4 A, B) adds further credence to the
importance of the network (Figure 4). The current finding that
TDP-43 regulates SOD1 is also consistent with a recent micro
array study, where a modest increase in SOD1 mRNA levels was
observed upon TDP knockdown [48]. The increase in SOD1
reporter mRNA levels as observed by qPCR analysis (Figure 5B)
upon TDP-43 knockdown could result because of alterations in
transcription or mRNA stability, brought about by TDP-43.
However the effect could also be mediated indirectly through an
unknown factor which may or may not involve splicing, another
known function of TDP-43. As the above experiments were
carried out using artificial cDNA SOD1 fusion constructs, such a
mechanism would not be observed. Thus, future work will be
required to address these possibilities and their importance in the
details of the mechanism of TDP-43 repression.
The data presented here (Figure 5A & 5B) revealed an
unexpected regulatory link associating TDP-43 and SOD1.
Interesting questions for future work will be to determine whether
mutant TDP-43 or the aggregated forms of wildtype TDP-43 lose
or gain function and how these processes might relate to SOD1
and the dominant toxic-gain-of-function phenotype.
Materials and Methods
Plasmids and reagents
The reporter assay plasmids were modified versions of the
plasmids used previously [14]. Three different native variants of
the human SOD1 promoter have been used in the study. A
promoter of length 2156 bp as reported in [16] was used for the
RNAi screening. Validation experiments were carried out using
reporter plasmids containing a promoter of length 2206 bases with
a Thymidine base at position 2141 which was cloned from the
genomic DNA isolated from HEK293 cells. HEK 293 [49] cells
were obtained from ATCC. Site directed mutagenesis of this
SOD1 promoter was carried out to generate the G at position
2141 to achieve a SOD1 promoter sequence similar to Ensembl
listed seq.: ENSG00000142168. Omega fragment of b-galactosi-
dase enzyme was cloned in to pcDNA3.1 vector as mentioned
earlier [14]. pBUDCE4.1-TDP-43, a human TDP-43 expression
vector provided by Dr. Jeffrey Elliot, was modified with an
insertion of a b-lactamase cassette derived from pcDNA3.1 vector.
The whole genome human siRNA library consisted of 21,125
pools and was procured from Dharmacon. Each siGENOME
Smartpool from the library contained 4 different siRNAs targeting
each gene product. On Target plus siRNAs were purchased from
Dharmacon. HeLa TetOn [50] (Clontech) cells used in the
screening were provided by Dr. Hongtao Yu. Lipofectamine
RNAimax was from Invitrogen. Polyethylenimine (PEI), 25 kD,
linear polymer was procured from Polysciences and dissolved in
water at 1 mg/ml. Validated qPCR primers (Origene) for the
targets were used in the study. Mouse anti WWC1 antibody was a
kind gift from Dr. Joachim Kremerskothen. Rabbit polyclonal
antibodies against COTL1, CCT8 and TDP-43 were purchased
from ProteinTech group.
Whole genome RNAi screening
5.6 ml of each 5 mM stock siRNA Smartpool (Dharmacon) was
picked using a Biomek FX (Beckmann coulter) and diluted in to
100 ml of OptiMEM I (Invitrogen) to achieve a concentration of
8 pmol/30 ml. 30 ml of the diluted siRNA was transferred to 96
are less than 2% of the total are not shown in the figure. C) Effect of siRNA knockdowns of SOD1 isoforms in the screen. The MAD score values of the
three SOD1 isoforms obtained in the screen are shown. The error bars represent SD.
doi:10.1371/journal.pone.0035818.g003
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RNAImax (1:75 v/v in OptiMEM I) was added using a Microflo
liquid dispenser (BioTek) on top of the diluted siRNA pools in
assay plates and incubated for 30 minutes at room temperature.
Appropriate volume of stock reporter plasmids were diluted in to
DMEM (Invitrogen) to generate 200 ng of A4V mutant SOD1-a
and 50 ng of v plasmids in 30 ml volume. Appropriate amounts of
PEI to achieve 5 ul/well was added to the diluted DNA, mixed
and incubated at room temperature for 15 min. After 15 minutes,
HeLa TetOn cells that had been trypsinized and re-suspended in
complete DMEM (DMEM+10%FBS+1% Penicillin/Streptomy-
cin) were mixed with the plasmid transfection reaction to obtain a
final concentration of 10,000 cells/140 ml. The mixture was
incubated at room temperature for 15 minutes. Following
Figure 4. Protein interaction network map of hits from the RNAi screen. The data from the RNAi screen was processed to calculate MAD scores
and was used for Ingenuity pathway analysis (IPA). The network annotated ‘‘Skeletal and Muscular System Development and Function, Tissue
Morphology, Inflammatory Response’’ ranked at the top with the highest score and is shown in the figure. The hits that increased SOD1 levels above 3SD
are shown in red and the ones that decreased the signal below 22SD are shown in green. The proteins represented by color-less nodes were below the
selection criteria. Direct interactions are shown in bold lines and indirect interactions are shown in broken lines. (See Table S1 for proteins in thisn e t w o r k )
doi:10.1371/journal.pone.0035818.g004
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to the ongoing RNAi transfection in the 96 well assay plates using
a Titertek liquid dispenser. The 96 well assay plate consisted of
columns 1 and 12 dedicated for controls and column 2 through 11
for test siRNA (Figure S2). The assay plates were incubated in a
5% CO2/37uC incubator for 96 hrs. Plates were decanted by
centrifugation and 50 ul of luminogenic substrate (Beta-glo assay
system (Promega) diluted 1:5 v/v in PBS/0.1% Tween 20) was
added to each well. Luminescence measurements were made using
a multi label plate reader (Envision, Perkin Elmer). The data
obtained were archived for later analyses.
Data analysis and pathway mapping
Data in triplicates from the 21,125 targets analyzed in the
screen were processed by two different methods to verify
consistency 1) MAD score and 2) Z score. Z score [51] method
uses the mean of the plate to normalize each well data, whereas
MAD score uses median absolute deviation [20] of the plate to
normalize each well data. They were calculated using the formula:
Z score=(Xi2X)/sx, MAD score=(Xi2~ X X)/MAD, where Xi is
fluorescent signal in each well, X is the plate mean, sx is the plate
standard deviation, ~ X X is plate median and MAD is median
absolute deviation of the plate. The NCBI accession ID of the
targets with varying hit selection criteria were uploaded in to the
Ingenuity pathway analysis program and analyzed using the IPA
Core analysis module for networks that are highly represented by
the hits. Networks with the lowest 2log P values indicate a
network with the largest number of hits mapped. The hits picked
for further analysis were confirmed to meet the false discovery rate
q* of ,0.05 (FDR was calculated using the Benjamini-Hochberg
method [21]
Monitoring changes in SOD1 level by b-galactosidase
reporter assay and Western blot analysis
For knockdown experiments, HeLa TetOn cells were plated in
a 6 well plate and grown overnight in an incubator. Cell samples
where then transfected with respective siRNA at a concentration
of 40 pmol/well using lipofectamine RNAimax according to
manufacturers’ instructions and incubated for 2 days. After this,
cells were transfected with respective reporter systems with PEI
and incubated for an additional 2 days. Approximately 96 hrs
after siRNA transfection, cells were lysed in 16 reporter lysis
buffer (Promega) containing 1 protease inhibitor cocktail mini
tablet/10 ml. Cell lysates were spun down for 2 min at 16000 g
and total protein content of the supernatant was determined by the
Bradford method (Biorad). A volume of each supernatant
containing 25 mg of total protein was added with fluorogenic
substrate, Fluorescein di-b-D-galactopyranoside (FDG) and the
fluorescence was measured (Ex: 490 nm, Em: 525 nm) in a M5
plate reader (Molecular devices). The initial velocity (Vo) of the
fluorescence change for the first 11 hrs (linear phase) of the kinetic
reaction was used in the calculation. Relative fold change was
calculated in reference to control or untreated samples. Volumes
containing 25 mg of total protein of the supernatant fraction were
loaded on a Tricine SDS-PAGE gel and proteins were transferred
to a nitrocellulose membrane and blotted with respective
antibodies. The blots were scanned using Typhoon imager (GE
Healthcare) and band intensity was quantified whenever required
Figure 5. Regulation of SOD1 levels by TDP-43. A) TDP-43 knockdown or over expression was carried out in HeLa TetOn cells expressing the
A4V reporter plasmids. Supernatant fractions were assayed for b-gal activity. Soluble SOD1 reporter expression levels (b-gal activity) relative to
controls (dotted line) are shown. Sample sizes ranged from 8 to 23. The error bars represent 95% confidence interval. B) Quantitative PCR analysis of
SOD1 reporter mRNA levels was carried out on total mRNA isolated from cells transfected with control or TDP-43 siRNA and A4VSOD1 reporter
plasmids. The SOD1 mRNA levels of TDP siRNA treated samples are shown relative to control (dotted line). The error bars represent 95% confidence
interval.
doi:10.1371/journal.pone.0035818.g005
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Averaging used for background correction.
Quantitative PCR analysis
Total RNA was isolated from cells using the RNAII isolation kit
(Clontech) following the manufacturers instructions. The amount
of total RNA was evaluated by Broad Range RNA quantification
Kit, using Qbit method (Invitrogen). cDNA synthesis from
equivalent amounts of the total RNA were performed with the
High Capacity cDNA synthesis kit from Applied Biosystems
following the manufacturers recommendations. Equivalent vol-
umes of cDNA were then used to set up qPCR reactions of the
appropriate target genes and controls using SYBRH GreenER
TM
qPCR Supermix (Invitrogen) according the manufacturers proto-
cols. qPCR analysis was carried out on an Applied Biosystems
7900HT Fast-Real time PCR system. The fold change in mRNA
levels was calculated by the 2
2DDCt method ([52]).
Supporting Information
Figure S1 Assay for soluble, folded SOD1. The assay
system consists of a vector driving expression of SOD1 fused to the
a-fragment of b-galactosidase and a separate vector driving
expression of the v-fragment of b-galactosidase. The structural
complementation of the a and the v fragments results in the
regeneration of b-galactosidase enzymatic activity that can be
measured by a luminogenic substrate. Any changes in biological
processes including degradation and aggregation that result in the
changes in the soluble levels of the SOD1-fusion will have a
concomitant change in luminescence.
(TIF)
Figure S2 siRNA screening transfection scheme. Co-
transfection scheme of the plasmid and siRNA as carried out in the
genome-wide screen. The sample distribution format in a 96 well
plate is also shown.
(TIF)
Figure S3 Changes in TDP-43 protein levels upon TDP-
43 knockdown and over expression. TDP-43 knockdown or
over expression was carried out in HeLa TetOn cells expressing
the A4V reporter plasmids. Supernatant fractions were run on
SDS-PAGE and transferred on to nitrocellulose membrane and
blotted with anti-TDP-43 antibody. TDP-43 protein levels (grey
bars) quantified from western blots normalized relative to controls
(dotted line) are shown.
(TIF)
Figure S4 Changes in SOD1 expression and target
mRNA and protein levels after knockdown of targets in
the TDP-43 protein interaction network. A) Relative SOD1
expression as measured by b-gal assay in cells transfected with
siGenome siRNA pools targeting 7 targets (upper left panel) that
increased SOD1 levels in the screen and 4 targets (upper right panel)
that decreased the SOD1 levels in the screen. All eleven targets are
connected in the protein interaction network (Figure 4 and Table
S1). Targets that were not statistically significant with P.0.01 in
the retest are shown as white bars. Target message levels measured
by qPCR in cells transfected with siGenome siRNA pools are
shown relative to controls (lower panel). B) SOD1 protein expression
measured by b-gal activity in supernatant fractions of cells
transfected with On Target plus siRNA relative to controls is
shown (left panel). The effects of all five targets were statistically
significant (P,0.01). Target message levels measured by qPCR in
cells transfected with On Target plus siRNA pools are shown (right
panel) relative to controls. C) Detection of target proteins by
western blotting of samples from cells treated with siGenome or
On Target Plus siRNA and their respective controls. The error
bars in the b-gal assay experiments represent a 95% confidence
interval. The error bars in qPCR experiments represent SD.
(TIF)
Table S1 List of proteins in the interaction network.
Proteins identified in the screen that are involved in the interaction
network annotated ‘‘Skeletal and Muscular System Development
and Function, Tissue Morphology, Inflammatory Response’’ and
represented in Figure 4. Gene symbol, NCBI Accession ID and
the respective MAD score are shown.
(DOC)
Table S2 Cellular modulators of Superoxide dismutase
1. The Gene symbol, equivalent human NCBI Accession ID and
MAD scores from the RNAi screen for ten cellular proteins
identified in an earlier cDNA expression screen (Table 1 [14]) for
gene products whose expression increased soluble SOD1. None of
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